ID | 118346 |
タイトル別表記 | Cancer genome profiling for GI cancers
|
著者 | |
キーワード | Comprehensive genomic profiling
gastrointestinal cancers
genotype-matched therapy
|
資料タイプ |
学術雑誌論文
|
抄録 | In Japan, cancer genome profiling (CGP) for cancer patients without standard treatment has been covered by public insurance since June 2019. This study analyzed data of 122 patients with gastrointestinal tumors who underwent CGP to clarify cancer genome medicine’s current status and possible problems at the Tokushima University Hospital. The major types of cancer included pancreatic (n = 30), colorectal (n = 25), biliary tract (n = 15), gastric (n = 11), and hepatocellular carcinoma (n = 8). CGP tests included F1CDx in 70 patients (57%), F1LCDx in 36 (30%), TSO500 in 14 (11%), and NCC Oncopanel in 2 (2%). Actionable gene alterations were identified in 72 patients (59%), but only 5 patients (4%) were treated for pancreatic (n = 1), colorectal (n = 3), and small bowel cancers (n = 1). The main reasons for not receiving genotype-matched therapy included the lack of appropriate drugs or clinical trials that matched the actionable gene alterations (n = 40) and the inability to participate in clinical trials (n = 10). There is still not a sufficient number of patients receiving genotype-matched treatment for gastrointestinal cancers. To promote cancer genome medicine in regional areas, attempts to improve access to genotype-matched therapies are required, as well as to promote the development of new molecular-targeted drugs and clinical trials for these drugs.
|
掲載誌名 |
The Journal of Medical Investigation
|
ISSN | 13496867
13431420
|
cat書誌ID | AA11166929
|
出版者 | Tokushima University Faculty of Medicine
|
巻 | 70
|
号 | 1-2
|
開始ページ | 154
|
終了ページ | 159
|
並び順 | 154
|
発行日 | 2023-02
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
病院
|